JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Taranabant (aslo known as MK-0364) is a novel, highly potent and selective cannabinoid 1 (CB1) receptor inverse agonist being investigated as a potential treatment for obesity due to its anorectic effects. It inhibits the binding and functional activity of various agonists, with a binding Ki of 0.13 nM for the human CB1R in vitro. Taranabant reduces abdominal pain and increases intestinal transit in mice. It was discovered by Merck & Co. In October 2008, Merck discontinued the phase III clinical trials due to high level of central side effects, mainly depression and anxiety.
References: J Med Chem. 2006 Dec 28; 49(26):7584-7; J Pharmacol Exp Ther. 2007 Jun; 321(3):1013-22.
Related CAS#: 701977-00-6 (Taranabant racemate); 701977-08-4 Taranabant (1R, 2R)stereoisomer
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!